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2 
I.	 Abstract 
 
REST/NRSF (Repressor Element-1 (RE1) Silencing Transcription 
Factor/Neuron-Restrictive Silencer Factor) is a gene-silencing factor that is widely 
expressed during embryogenesis and plays a strategic role in neuronal differentiation. 
Recent studies indicate that REST can be activated in differentiated neurons during a 
critical window of time in postnatal development and in adult neurons in response to 
neuronal insults such as seizures and ischemia. However, the mechanism by which 
REST is activated in neurons is, as yet, unknown. Here I show that REST is controlled 
at the level of protein stability via ?-TrCP-dependent, ubiquitin-based proteasomal 
degradation in differentiated neurons under physiological conditions and identify CK1 
as an upstream effector that regulates REST cellular abundance. CK1 associates with 
and phosphorylates REST at two neighboring, but distinct motifs within the 
carboxy-terminus of REST critical for binding of ?-TrCP and targeting of REST for 
proteasomal degradation. I further show that global ischemia in vivo triggers a 
decrease in CK1 and increase in REST in selectively-vulnerable hippocampal CA1 
neurons. Administration of the CK1 activator pyrvinium pamoate by in vivo injection 
immediately after ischemia restores CK1 activity, suppresses REST expression and 
rescues neurons destined to die. My results identify a novel and previously 
unappreciated role for CK1 as a brake on REST stability and abundance and reveal 
that loss of CK1 is causally-related to ischemia-induced neuronal death. These 
findings point to CK1 as a potential therapeutic target for the amelioration of 
hippocampal injury and cognitive deficits associated with ischemic stroke.  
 
 
 
 
3 
II.	 Background  
 
The transcriptional repressor REST is a gene silencing transcription factor that 
represses an array of coding and noncoding neuron-specific genes including synaptic 
vesicle proteins, neuroreceptors and channels, and microRNAs1-4). REST is widely 
expressed during embryogenesis but declines in expression during neuronal 
differentiation. REST downregulation is critical to acquisition of the neural phenotype. 
In mature neurons REST is quiescent, but can be activated in hippocampal neurons 
during normal postnatal development, driving the switch from immature to mature 
NMDA receptors5) and in selectively-vulnerable hippocampal neurons by ischemic 
insults6-8).  
 
In cancer cells and pluripotent stem cells, REST is bi-directionally regulated by ?
-TrCP-dependent, ubiquitin-based proteasomal degradation9-11) and 
HAUSP-dependent deubiquitination12). In the transition from neural progenitors to 
neurons, REST is downregulated by transcriptional repression and protein 
degradation1). REST harbors two neighboring, but distinct, noncanonical degron 
motifs, in its carboxy-terminus13). Phosphorylation of serine residues within these 
motifs enables binding by the E3 ubiquitin ligase ? -TrCP, priming REST for 
ubiquitin-based proteosomal degradation. Whereas the mechanism by which REST 
expression is regulated in stem cells and cancer cells is established, the upstream 
kinase that phosphorylates REST is, as yet, unknown. 
 
CK1 is a serine/threonine kinase that is evolutionary conserved and plays a pivotal 
role in membrane transport, cell division, DNA repair, and activation of transcription 
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factors such as ?-catenin and p5314, 15). CK1 has seven isoforms, each encoded by 
a unique gene. CK1? and ? are abundantly expressed in hippocampus, where 
they regulate NMDAR function16) and are activated by group I mGluRs17). A prevailing 
view is that CK1 family members are constitutively active. 
 
The present study was undertaken to identify the responsible kinase for degradation 
of REST and characterize the mechanism by which REST is activated in adult 
neurons in response to neuronal insults. Here I identify CK1 as the upstream kinase 
that associates with and phosphorylates serine residues at carboxy-terminus in REST 
and targets REST for ?-TrCP-dependent, ubiquitin-based proteasomal degradation. 
Global ischemia in vivo triggers a decrease in CK1, thereby increasing REST in CA1 
neurons. A single, acute injection of the CK1 activator pyrvinium after the ischemic 
episode affords robust neuroprotection in a clinically-relevant model of stroke. My 
results point to CK1 as a brake on REST expression and reveal that loss of CK1 in 
response to ischemic insults is causally-related to neuronal death. 
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III.	 Aim of Study 
 
1.	 To identify the kinase which phosphorylates REST and induces degradation of 
REST. 
 
2.	 To investigate the impact of the kinase which is identified in Aim 1 on neuronal 
cell death in CA1 after global ischemia. 
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IV.	 Methods 
 
1.	 Cell culture, drug treatment and transfection.  
HeLa and N2A cells were plated on culture dishes or plates maintained in DMEM 
supplemented with 10% FBS in an incubator with an atmosphere of 10% CO2 at 37 
ºC. Cells were grown to 70-80% confluency for drug treatment or transfection. To 
monitor the impact of CK1 and other kinases on REST, cells were treated with the 
CK1 activator pyrvinium pamoate (Sigma), the CK1 inhibitors D4476 (Tocris), the 
PKA inhibitor H89 (Sigma) or the PI3 kinase inhibitor LY294002 (Sigma) at indicated 
concentrations for 4 h. Pyrvinium pamoate is reported to be a highly selective 
activator of CK1, ~tenfold more potent as an activator of purified CK1 vs. its action 
as an inhibitor of Wnt signaling at sub-nanomolar concentrations18), but  see 19). To 
monitor the impact of CK1 on the rate of protein degradation, HeLa cells were 
treated with pyrvinium (10 µM) or D4476 (10 µM) for 2 h prior to application of the 
protein synthesis inhibitor cycloheximide (100 µg/ml, Calbiochem). At indicated 
times, whole cell lysates were prepared and subjected to Western blot analysis. 
Immunoblots were probed with antibodies to REST or ?-actin antibody. Cells were 
transfected with various constructs using Lipofectamine 2000 (Invitrogen). 
 
2.	 Primary cultures of hippocampal neurons and oxygen-glucose deprivation (OGD).  
Primary cultures of hippocampal neurons were prepared from embryonic (E18) rats 
as described8). Cultures were maintained 14 days in vitro (DIV) prior to experiments. 
To monitor the impact of CK1 on REST, neurons were treated with pyrvinium (10 
µM), D4476 (10 µM), or clasto-lactacystin ? -lactone (lactacystin, 2.5 µM, 
Calbiochem) for 24 h. To induce OGD, primary cultures of hippocampal neurons 
were exposed to serum-free, glucose-free medium saturated with 95% N2/5% CO2 
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(30 min at 37°C) in an airtight, anoxic chamber (Billups-Rothenberg). Cultures were 
returned to oxygenated, glucose-containing medium under normoxic conditions for 
24 h and were used for western blotting analysis. 
 
3.	 Plasmids.  
Myc-CK1 and shCK1 constructs were kind gifts from Dr. Hiroyuki Inuzuka. 
HA-REST construct was obtained Dr. Michele Pagano. HA-REST mutants were 
generated using the PfuTurboDNA Polymerase (Stratagene) according to the 
manufacturer’s instructions.  
 
4.	 shRNAs and lentiviral vectors.  
CK1? shRNA, ?-TrCP1/2 and nontargeting (NT) shRNA, a silencer-resistant 
sequence that does not target any known eukaryotic gene sequence, were 
engineered in the pcDNATM 6.2-GW/EmGFP shRNA expression vector (Invitrogen): 
CK1? shRNA (5?- TAC ATG AGC ACA TAG CCC AGG -3?), ?-TrCP1 (5?- AAC 
TCT TCC AGA ATG CTC CAC-3?) or (5?- TAT GAA ATC CCT CTG CAG CAT -3?), 
?-TrCP2 (5?- TCA TAC TGG AGG CAG AGG ACA -3?) and NT shRNA (5?-AAA 
TGT ACT GCG CGT GGA GAC-3?). For RNAi-mediated silencing of CK1? or ?
-TrCP in cultured hippocampal neurons, shRNA was cloned from the pcDNATM 
6.2-GW/EmGFP expression vector into a self-inactivating lentiviral vector 
pRRLsin.cPPT.CMV.eGFP.Wpre8, 20). High-titer vesicular stomatitis virus-pseudo 
-typed lentiviral stocks were produced in HEK-293T cells as described 8, 20). In brief, 
cells were transfected with pRRL.PPT.hCMV.GFP.shRNA.Wpre transfer construct, 
pMDLg/pRRE and pRSV-REV packaging constructs, and the envelope protein 
construct pMD2.G by means of calcium phosphate. Titers were determined by 
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infecting HEK-293T cells with serial dilutions of concentrated lentivirus. eGFP 
fluorescence was evaluated by flowcytometry at 48 h after transduction; Titers were 
1 × 109 transducing units. The efficacy of CK1?  and ?-TrCP shRNA was 
evaluated by Western blot 7 d after transduction of primary hippocampal neurons 
prepared from the brains of E18 Sprague Dawley rats. 
 
5.	 Western blots and immunoprecipitation.  
Western blot analysis was performed as described5, 21). In brief, cells were washed 
with cold PBS and lysed in buffer containing (in mM): 25 Tris-HCl, pH 7.4, 150 NaCl, 
1 EDTA, 1X protease inhibitor cocktail (Sigma), 0.1% SDS and 0.5% Na 
deoxycholate.  For the tissue samples, hippocampi were rapidly dissected and 
transverse slices of dorsal hippocampus (1 mm) were cut with a Mcllwain tissue 
chopper. The CA1 subfield was rapidly microdissected and lysed in buffer 
supplemented with a 1% cocktail of protease inhibitors (Sigma). Protein 
concentrations were measured by means of the bicinchoninic acid (BCA) assay 
(Pierce). Equal aliquots of protein (50 ?g) were subjected to SDS-PAGE (4-20%), 
transferred to a nitrocellulose membrane and processed for incubation with antibody 
(anti-REST, 1:1000, Millipore; anti-CK1?, 1:500, Santa Cruz, anti-CK1?, 1:1000, 
BD Bioscience; anti-?-TrCP, 1:1000, Cell signaling; anti-ubiquitin, 1:1000, Cell 
signaling; anti-myc, 1:1000, Cell signaling; anti-Flag, 1:2000, Millipore; anti-HA, 
1:1000, Covance; anti-?-actin, 1:50000, Sigma). Membranes were washed and 
reacted with enhanced chemiluminescence reagent (ECL; Amersham Biosciences). 
For immunoprecipitation, 500-1000 ?g lysates were incubated with the appropriate 
antibody (1-10 ?g) overnight at 4 ?C followed by one hour-incubation with 
Protein G sepharose beads (Millipore). Immuno-complexes were washed five times 
 
9 
with IP buffer containing (in mM): 25 Tris-HCl, pH 7.4, 150 NaCl, 1 EDTA, 1 EGTA 
and 0.5% Triton X-100) before being resolved by SDS-PAGE and immunoblotted 
with indicated antibodies. Band densities were normalized to ?-actin. Mean band 
densities for samples from experimental animals were normalized to the 
corresponding samples from sham animals.  
 
6.	 qRT–PCR.  
Cells were washed twice with cold PBS and RNA was extracted using TRIzol 
(Invitrogen). RNA concentration was measured by means of a Nanodrop (NanoDrop 
Technologies). Aliquots of RNA (1 ?g) were reverse-transcribed to cDNA with 
Superscript III Reverse Transcriptase (Invitrogen). Quantitative real-time PCR 
(qPCR) was performed with TaqMan probes (Applied Biosystems) for REST (Ref: 
Hs00958503_m1); GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (Ref: 
Hs02758991_g1) served as an endogenous reference. Reactions were run in 
triplicate in a StepOnePlus real-time PCR system (Applied Biosystems). mRNA 
abundance was calculated by means of the comparative Ct method at a threshold of 
0.02. Relative expression ratios were calculated by normalization of values for 
experimental samples to those of the corresponding sham controls by means of the 
relative expression software tool (REST©) on the basis of the group mean for the 
target transcript versus reference GAPDH transcript22).  
 
7.	 In vitro phosphorylation assay.  
To assess phosphorylation of REST, N2A cells were transfected with 
HA-conjugated WT and mutant REST using Lipofectamine 2000.  Forty-eight 
hours post-transfection, cells were rinsed with ice-cold PBS and pelleted by 
centrifugation and lysed in lysis buffer. Lysates (750 ?g) were immunoprecipitated 
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with anti-HA agarose conjugate (Sigma). Immunoprecipitated HA-REST was 
incubated with recombinant active CK1? (New England BioLabs) in a reaction mix 
containing 1X assay buffer (50 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM EGTA, 
0.4 mM DTT, and 1X Protease Inhibitor Cocktail (Sigma)), 60 µM Mg-ATP, 0.3 µCi
?-32P-ATP (3000 Ci/mmol) (Perkin Elmer) and 1 unit/µl CK1? at 30˚C for 30 min. 
The reaction was stopped by the addition of ice-cold radioimmune assay buffer 
containing (in mM): 10 Tris-HCl, pH 7.4, 75 NaCl, 20 EDTA, 10 EGTA, 20 Na 
-pyrophosphate, 50 NaF, 20 glycerol-2-phosphate, and 1 p-nitrophenylphosphate, 
and stripped with loading buffer (Invitrogen).  Samples were run on 3-8% 
Tris-acetate gels (Invitrogen) for subsequent autoradiography and Western blotting. 
 
8.	 Animals.  
Age-matched adult male Sprague-Dawley rats weighing 150-200 gram (Charles 
River Laboratories, Inc.) were maintained in a temperature- and light-controlled 
environment with a 12:12 h light/dark cycle and were treated in accordance with the 
principles and procedures of the National Institutes of Health Guidelines for the 
Care and Use of Laboratory Animals. Protocols were approved by the Institutional 
Animal Care and Use Committee of the Albert Einstein College of Medicine. 
 
9.	 Global ischemia.  
Animals were subjected to transient global ischemia by the four-vessel occlusion 
paradigm as described8, 21). For sham surgery, animals were subjected to the same 
anesthesia and surgical conditions, except that the carotid arteries were not 
occluded. Body temperature was maintained at 37.5 ± 0.5 °C by external warming 
until recovery from anesthesia. Animals that failed to show complete loss of the 
righting reflex and dilation of the pupils 2 min after occlusion was initiated and the 
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rare animals that exhibited obvious behavioral manifestations (abnormal 
vocalization when handled, generalized convulsions, loss of > 20% body weight by 
3-7 d or hypoactivity) were excluded from the study.  
 
10.	 Drug injections in vivo.  
Lactacystin (1 ?g/?l, dissolved in DMSO) or DMSO was administered to rats by 
stereotaxic injection directly into the right hippocampal CA1 (3.0 mm posterior and 
2.0 mm lateral to bregma, 4.0 mm below the skull surface) using a 28-gauge needle 
and a Hamilton syringe at a flow rate of 0.2 µl/min (total 4 µl). The needle was left in 
place for an additional 5 min and then gently withdrawn. The CA1 subfield was 
rapidly microdissected at 24 h after injection and used for Western blot analysis 
(see below). Pyrvinium (1 mM, dissolved in DMSO) or DMSO was administered to 
animals immediately after ischemia or sham surgery by intracerebroventricular (icv) 
injection. For icv injection, a 28 gauge needle attached to a Hamilton syringe was 
stereotaxically lowered into the right lateral ventricle at a flow rate of 1 µl/min (total 5 
µl) to a position defined by the following coordinates relative to bregma: 0.92 mm 
posterior, 1.2 mm lateral, 3.6 mm below the skull surface. 
 
11.	 Histology and Fluoro-Jade labeling.  
Neuronal cell loss was assessed by histological examination of brain sections at the 
level of dorsal hippocampus from animals killed at 7 days after sham surgery or 
global ischemia. Animals were anesthetized with halothane and transcardially 
perfused using 0.9% saline with heparin followed by ice-cold 4% paraformaldehyde 
in PBS (0.1 M, pH 7.4). Brains were removed and immersed in fixative. Coronal 
sections (20 µm) were cut at the level of the dorsal hippocampus with a cryotome 
and processed for staining with toluidine blue or Fluoro-Jade C (Millipore). The 
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number of dying pyramidal neurons per 250-mm length of the medial CA1 region 
from 4 ~ 6 rats per group (8 sections per rat) was counted under a fluorescence 
microscope at x 40 magnification. 
 
12.	 Statistical analysis.  
For qRT-PCR, significance was assessed by means of the randomization test (Pfaffl 
et al., 2002) and a Student's t-test (unpaired, two-tailed). For Western band 
densities and radioactive band densities, significance was assessed by means of 
the Student's t-test (unpaired, two-tailed). P < 0.05 was considered to be statistically 
significant. 
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V.	 Results 
 
1.	 CK1 as a responsible kinase of REST for ?-TrCP-dependent, ubiquitin-based 
proteasomal degradation.  
(1)	 CK1 regulates REST protein stability. 
I first sought to identify the upstream kinase for phosphorylation of residues critical to 
recognition of REST by ?-TrCP, a member of the F-box family of E3 ligases, which 
initiates ubiquitination of many transcription factors and other target proteins. 
Toward this end, I used the protein kinase prediction algorithm Motif Scan set at low 
stringency23). Among the protein kinases delineated by Motif Scan, Casein Kinase 1 
(CK1) was predicted to phosphorylate REST at S1027, a residue within the motif 
which was shown to be recognized by?-TrCP. CK1 phosphorylates sites within or 
near the degron motifs of several other proteins, priming them for ubiquitin-based 
proteasomal degradation in a ? -TrCP-dependent manner, including the 
transcription factor ?-catenin24), CDC25A, a phosphatase involved in cell division25) 
and UHRF1 (ubiquitin-like, with PHD and RING finger domains), an epigenetic 
protein involved in maintenance of DNA methylation during DNA replication26).  
 
To examine a possible role for CK1 in regulation of REST protein abundance, I used 
a combination of pharmacological and genetic approaches. HeLa cells express 
REST at high levels and are readily amenable to genetic manipulation. Application of 
the CK1 activator pyrvinium to HeLa cells decreased REST protein abundance in a 
dose-dependent manner (Fig. 1a). CK1 inhibitors D4476 (Fig. 1b) and IC261 (data 
not illustrated) each increased REST expression. As expected, D4476 blocked the 
pyrvinium-induced increase in REST (Fig. 1c). These findings indicate that CK1 
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activity negatively regulates REST expression. To examine whether CK1 abundance 
is causally related to REST protein abundance, I genetically manipulated CK1 and 
assessed cellular levels of REST protein. Overexpression of Myc-tagged CK1 
isoforms ?1, ?2, ?, and ? (but not ?1, ?2, or ?3) decreased REST protein 
abundance, as assessed by Western blot analysis (Fig. 1d). Consistent with this, 
expression of shRNA constructs targeting CK1?  (~60% knockdown), CK1? 
(~40% knockdown) or a chained construct containing both shRNAs and thereby 
targeting CK1? and ? (50% knockdown of CK1?; 60% knockdown of ?), but 
not NT shRNA, increased REST protein abundance (Fig. 1e). Collectively, these 
findings indicate that CK1 regulates REST protein expression in HeLa cells, but do 
not address whether CK1 regulates REST in neurons. To address this issue, I next 
examined the impact of CK1 on REST protein abundance in hippocampal neurons in 
vitro. Whereas activation of CK1 by pyrvinium decreased REST expression in 
neurons, inhibition or shRNA-mediated knockdown of CK1 increased REST (Fig. 1f). 
To evaluate a possible role for other kinases in regulation of REST protein levels, I 
examined the effect of inhibitors of other kinases on REST protein levels. Neither 
H89, an inhibitor of protein kinase A (Fig. 2a) nor LY294002, an inhibitor of 
phosphoinositide 3-kinase (Fig. 2b), significantly altered REST protein levels, 
indicating specificity of CK1 in regulation of REST expression. 
 
The results thus far document a role for CK1 in REST protein expression, but do not 
address the mechanism by which CK1 may exert its effect. A reduction in protein 
could arise as a consequence of reduced protein synthesis and/or enhanced protein 
degradation. To examine whether CK1 regulates REST at the level of transcription, I 
examined the impact of the CK1 activator pyrvinium and the inhibitor D4476 on 
REST mRNA by quantitative RT-PCR (qRT-PCR). Neither pyrvinium nor D4476 
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detectably altered REST mRNA expression (Fig 2c). Moreover, neither 
overexpression of myc-tagged CK1?1, ?2, ?, ?, ?1, ?2, or ?3 (Fig. 2d), nor 
shRNA-mediated knockdown of CK1 ?, ? or ? and ? (Fig. 2e), detectably 
altered REST mRNA, consistent with regulation at the post-transcriptional level. I 
next examined whether CK1 regulates REST at the level of protein stability. Toward 
this end, I treated cells with the protein synthesis inhibitor cycloheximide (100 µg/ml) 
in the absence or presence of the CK1 activators pyrvinium or CK1 inhibitor D4476 
and measured REST protein abundance over time. This protocol affords a measure 
of constitutive protein degradation. In the presence of cycloheximide, levels of REST 
protein declined. Whereas pyrvinium increased (Fig. 3a), D4476 attenuated (Fig. 3b) 
the rate of REST protein degradation. Collectively, these data indicate that CK1 
negatively regulates REST abundance at the level of protein stability. 
 
(2)	 CK1 associates with and phosphorylates REST, thereby promoting ?-TrCP 
-mediated ubiquitination. 
?-TrCP recognizes and binds phosphorylated serine residues in canonical and 
non-canonical degron motifs within target proteins, directing them to ubiquitin-based 
proteasomal degradation26, 27). Humans and rats both express two ?-TrCP genes, 
?-TrCP1 and ?-TrCP2. Whereas both proteins are functional in humans, rats 
express a short, truncated ?-TrCP2, which lacks both the D-domain and the F-box 
like domain present in ?-TrCP1 and is therefore nonfunctional. I therefore focused 
on ?-TrCP1. REST contains two neighboring, but distinct, degron motifs which 
serve as ?-TrCP binding sites, one containing E1009 and S10139) and the other 
containing S1024, S1027 and S103011) (Fig. 4a). Whereas it is known that 
phosphorylation of these serine residues is critical for recognition by ?-TrCP, the 
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kinase that phosphorylates these residues in REST is, as yet, unknown. To address 
this issue, I first examined whether CK1 physically associates with REST. CK1? 
physically associated with endogenous REST, as assessed by 
co-immunoprecipitation (Fig. 4b). 
 
To identify residues phosphorylated by CK1, I used site-directed mutagenesis to 
mutate serine residues in and around the two degron motifs singly or in combination 
to the non-phosphorylatable residue alanine. WT and mutant HA-REST constructs 
were expressed in N2A cells and immunoprecipitated with an antibody directed to 
HA. N2A cells are a neuron-like cell that express very low levels of full-length REST 
and are therefore suitable for evaluation of mutant REST constructs. 
Immunocomplexes were subjected to an in vitro phosphorylation assay in the 
presence and absence of recombinant CK1?. CK1? induced striking 
phosphorylation of WT REST (Fig. 5a-c). Several single point mutations (S1013A, 
S1024A and S1030A) reduced CK1-dependent phosphorylation of REST (Fig. 5a), 
consistent with the notion that loss of a single serine residue is sufficient to reduce 
REST phosphorylation. Importantly, the double REST mutant E1009A/S1013A and 
triple REST mutant S1024A/S1027A/S1030A shown by others to abolish ?-TRCP 
binding9, 11), also abolished CK1-dependent phosphorylation of REST (Fig. 5b). 
Moreover, two additional constructs, the double REST mutant, S1013A/S1030A, and 
the quadruple mutant, S1013/S1024A/S1027A/S1030A, each markedly reduced 
CK1-dependent phosphorylation (Fig. 5c). Importantly, CK1 increased association of 
?-TrCP with REST (Fig. 6a, upper) and REST ubiquitination, as assessed by 
immunoprecipitation (Fig. 6a, lower). Moreover, expression of two shRNA constructs 
targeting ?-TRCP1/2 (?-TRCP1/2 shRNA-1, ~60% knockdown; ?-TRCP1/2 
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shRNA-2, ~30% knockdown), but not NT shRNA, markedly upregulated REST in 
hippocampal neurons (Fig. 6b), demonstrating an inverse causal relation between 
?-TRCP and REST. Collectively, these data demonstrate that CK1 phosphorylates 
serine residues contained within the two degron motifs of REST, increases 
association of ?-TrCP with REST and promotes ubiquitination of REST. 
 
(3)	 REST is targeted to the proteasomal degradation pathway in neurons. 
The results thus far demonstrate that CK1 is necessary and sufficient for 
phosphorylation of serine residues in the degron motifs within the REST 
carboxy-terminal domain, association of ? -TrCP with REST and REST 
ubiquitination, but do not examine a role for proteasomal degradation of REST. 
Whereas ?-TRCP-dependent proteasomal degradation in regulation of REST in 
cancer cells and pluripotent and neural stem cells is well-established26, 27), its role in 
regulation of REST in neurons is as yet unclear. To address this issue, I first 
examined the impact of the proteasomal inhibitor lactacystin on REST abundance in 
the hippocampal CA1 under physiological conditions. Lactacystin injected directly 
into the CA1 of control animals increased REST abundance and enhanced global 
protein ubiquitination in the CA1, consistent with a role for proteasomal degradation 
in maintenance of REST at low, constitutive levels in adult neurons under 
physiological conditions (Fig. 7a).  
 
I next examined a role for proteasomal degradation in regulation of REST 
abundance in insulted neurons. Neuronal insults such as global ischemia increase 
REST protein expression and induce silencing of target genes such as GluA2. This, 
in turn, leads to an increase in GluA2-lacking, Ca2+-permeable AMPARs in 
selectively vulnerable hippocampal neurons, events causally related to neuronal 
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death6, 8, 28). This is significant in that GluA2-lacking AMPARs are implicated in 
ischemia-induced neuronal death. Toward this end, I induced oxygen-glucose 
deprivation (OGD), an in vitro model of global ischemia, in hippocampal neurons in 
vitro. Under control conditions, application of the proteasomal inhibitor lactacystin 
did not detectably alter ?-TRCP, but increased REST and decreased the REST 
target gene GluA2. OGD induced upregulation of REST and downregulation of 
GluA2. In neurons subjected to OGD, application of lactacystin did not alter ?
-TRCP or further alter REST or GluA2 (Fig. 7b). These findings demonstrate that 
REST is upregulated by ischemic insults and degraded by proteasomal pathway in 
hippocampal neurons. 
 
2.	 CK1 as a therapeutic target after global ischemia.  
(1)	 Global ischemia decreases CK1 and promotes upregulation of REST in the CA1. 
To examine a role for CK1 and ubiquitin-based proteasomal degradation in 
upregulation of REST in the hippocampal CA1 in a clinically-relevant model of 
ischemic stroke, I subjected animals to global ischemia in vivo. Global ischemia 
induced by four-vessel occlusion (10 min) in rats causes selective, delayed neuronal 
death and delayed cognitive deficits (reviewed in 21)). Pyramidal neurons in the 
hippocampal CA1 are particularly vulnerable. Histological evidence of degeneration 
is not observed until 2-3 days after ischemia, affording a substantial window of time 
for molecular studies. I evaluated CK1?, CK1?, ?-TrCP, Cul1 and HAUSP 
expression in the CA1 of animals subjected to global ischemia or sham operation. 
Cul1 is a component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase 
complex27). HAUSP is a deubiquitylase known to stabilize REST12). Under basal 
conditions, CK1?, CK1?, ?-TrCP, Cul1 and HAUSP were robustly expressed in 
the CA1 of adult rats. By contrast, REST was detectable, but at very low levels. 
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Global ischemia mildly decreased?-TrCP and markedly reduced CK1? and CK1?
protein abundance, with little or no change in Cul1 or HAUSP. By contrast, ischemia 
markedly increased REST protein abundance in the CA1 (Fig. 8a,b).   
 
(2)	 CK1 activation protects against ischemia-induced neuronal death 
To examine whether loss of CK1 is causally related to ischemia-induced 
upregulation of REST and neuronal death, I examined the ability of CK1 activation to 
repress REST and rescue CA1 neurons from ischemia-induced neuronal death. 
Toward this end, I injected the CK1 activator pyrvinium icv immediately after 
induction of global ischemia in vivo. Whereas rats subjected to global ischemia 
exhibited robust neuronal death in the CA1 7 d after insult, as assessed by histology 
and Fluoro-Jade staining (Fig. 9a,b), neuronal death was significantly reduced in rats 
injected with pyrvinium immediately following ischemia. To investigate a possible 
mechanism for the CK1 activator-induced neuroprotection, I analyzed the impact of 
pyrvinium on REST and GluA2 protein levels in the CA1 of rats subjected to global 
ischemia. Pyrvinium rescued the ischemia-induced increase in REST and decrease 
in GluA2  (Fig. 10a,b), consistent with a model whereby CK1 promotes targeting of 
REST for proteasomal degradation, and unsilencing of GluA2. These findings 
demonstrate an inverse causal relation between CK1 and neuronal death of CA1 
neurons and implicate CK1 as a putative target for therapeutic intervention in 
ischemic stroke. 
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VI.	 Discussion 
 
In this study I identify CK1 as an upstream kinase that regulates REST cellular 
abundance and show that REST is regulated at the level of protein stability via ?
-TrCP-dependent, ubiquitin-based proteasomal degradation in differentiated neurons 
under physiological conditions. CK1 associates with and phosphorylates REST at two 
neighboring, but distinct motifs within the carboxy-terminus of REST essential to 
binding by ?-TrCP (the degron motifs), thereby priming REST for ubiquitin-based 
proteasomal degradation. Activation or overexpression of CK1 promotes REST 
ubiquitination and degradation in a ? -TrCP-dependent manner. Inhibition or 
RNAi-mediated knockdown of CK1 promotes REST stability and increases REST 
cellular levels. These findings establish an inverse causal relation between CK1 and 
REST abundance. I further show that ischemia triggers a decrease in CK1 and an 
increase in REST in selectively vulnerable CA1 pyramidal neurons. This is significant 
in that activation of REST is causally linked to ischemia- and seizure-induced 
neuronal death. A single, acute injection of the CK1 activator pyrvinium to rats 
immediately after an ischemic episode restores decreases REST and rescues CA1 
neurons destined to die. Collectively, these results identify a novel and previously 
unappreciated role for CK1 as a brake on REST stability and abundance and reveal 
that loss of CK1 is causally related to neuronal death in a clinically-relevant model of 
ischemic stroke. This is the first demonstration that CK1 directly phosphorylates 
REST in any cell type and that REST is regulated by proteasomal degradation in 
mature neurons. 
 
Findings in the present study are consistent with a model whereby REST is normally 
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quiescent, but can be re-activated in differentiated neurons during postnatal 
development in an experience-dependent manner5) and in response to neuronal 
insults such as ischemia6, 8) and seizures 29, 30). Under physiological conditions, CK1 
(the upstream effector) maintains REST at low, constitutive levels in differentiated 
neurons. CK1 associates with and phosphorylates REST at specific serine residues 
within the two degron motifs, enabling recognition by the E3 ligase ?-TrCP (Fig. 11). 
Upon binding, ?-TrCP poly-ubiquitinates the substrate, priming it for ubiquitin-based 
proteasomal degradation. Ischemic insults blunt CK1 and ? -TrCP, inducing 
upregulation of REST in selectively-vulnerable hippocampal neurons. Upon activation, 
REST binds to the RE1 element within the promoter of target genes important to 
synaptic function such as GluA2 and orchestrates the assembly of the corepressor 
complex (mSin3A and CoREST, HDACs 1 and 2 and G9a). The corepressor complex 
promotes epigenetic remodeling of core histone proteins at the promoter of target 
genes and represses transcription of genes important to synaptic plasticity and 
neuronal survival.  
 
The present study sheds light on the mechanism by which CK1 regulates REST 
cellular levels.  CK1 associates with REST and phosphorylates serine residues in the 
two degron motifs, enabling binding of ?-TrCP and activation of the ubiquitin-based 
proteasomal degradation pathway. Importantly, both the double mutant 
E1009A/S1013A and the triple mutant S1024A/S1027A/S1030A shown by others to 
abolish ?-TRCP binding9, 11), also abolishes CK1-dependent phosphorylation of 
REST, consistent with a cooperative/synergistic interaction between the two motifs. 
Interestingly, loss of several individual serine residues within or in close proximity to 
the motifs is sufficient to reduce CK1-dependent phosphorylation of REST. My 
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findings do not, however, rule out the possibility that not only CK1, but also other 
protein kinases, phosphorylate serine residues within the degron motifs, or other 
serine residues in REST and thereby regulate cellular abundance of REST. Moreover, 
I cannot rule out the possibility that other signaling pathways regulated by CK1, as for 
example the Wnt-?-catenin pathway, may contribute to the neuroprotective effects of 
pyrvinium. Further study will be necessary for detecting other kinases which regulates 
REST protein abundance and other pathways involved in neuroprotection caused by 
pyrvinium pamoate.  
 
Findings in the present study have broad implications for amelioration of the 
neurodegeneration and cognitive deficits associated with ischemic stroke. Importantly, 
dysregulation of REST and its target genes are implicated not only in ischemic stroke, 
but also in the pathogenesis of medulloblastomas, epilepsy, Huntington’s disease and 
SMCX, a form of X-linked mental retardation2, 3, 29). Thus, my findings implicate CK1 
as a therapeutic target not only for ischemic stroke but other brain disorders that 
involve dysregulation of REST in neurons.  
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VII.	 Conclusion 
 
The present study demonstrates CK1 directly phosphorylates REST, causing REST 
degradation, and CK1 would be a new therapeutic target in global ischemia. 
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Figure 9. 
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Figure 11. 
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X.	 Figure Legends 
 
Figure 1.	 CK1 regulates REST protein abundance.  
(a) Upper, representative Western showing that the CK1 activator, pyrvinium, reduces 
REST protein abundance in HeLa cells in a dose-dependent manner. Lower, 
summary data. (b) Upper, representative Western showing that the CK1 inhibitor 
D4476 increases REST protein abundance in a dose-dependent manner. Lower, 
summary data. (c) Pyrvinium reverses the increase in REST elicited by D4476. Lower, 
summary data. (d) Upper, representative Western blot showing overexpression of 
CK1 ?1, ?2, ? , or ? , but not ?1, ?2, or ?3, decreases REST protein 
abundance. Lower, summary data. (e) Upper, representative Western blot showing 
that two shRNAs targeting different sequences in CK1? and CK1?, but not NT 
shRNA, increases REST protein abundance in HeLa cells. Lower and right, summary 
data. (f) Upper, representative Western blot showing that pyrvinium decreases and 
D4476 and shRNA to CK1? increases REST protein levels in cultured hippocampal 
neurons Lower: summary data. n = 3 per treatment group/ 3 independent experiments.  
Here and in Figs. 2-10, data represent mean ± SEMs. ***, p < 0.001, **, p < 0.01, *, p 
< 0.05. 
 
Figure 2.	 CK1 post-transcriptionally regulates REST abundance.  
(a,b) Upper, representative Western blot showing REST protein abundance is 
unchanged in HeLa cells treated with the PKA inhibitor H89 (a) and the PI3 kinase 
(PI3K) inhibitor LY294002 (b). Lower, summary data. (c-e)  REST mRNA levels were 
unchanged in HeLa cells after treatment with pyrvinium or D4476(c), myc-CK1 (d), or 
shRNA to CK1 (e). n = 3 per treatment group/ 3 independent experiments.   
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Figure 3.	 CK1 post-translationally regulates REST degradation.  
(a,b) To monitor the impact of CK1 on the rate of protein degradation, HeLa cells were 
treated with pyrvinium (10 µM, a) or D4476 (10 µM, b) for 2 h prior to application of the 
protein synthesis inhibitor cycloheximide (100 µg/ml). At indicated times, whole cell 
lysates were prepared and immunoblots probed with REST or ?-actin antibody. n = 
3 per treatment group/ 3 independent experiments. *, p < 0.05. 
 
Figure 4.	 CK1 associates with REST.  
(a) Diagram illustrates serine residues within two noncanonical degron motifs in the 
carboxy-terminus of REST and critical to recognition by ? -TrCP. (b) 
Co-immunoprecipitation of recombinant Myc from HeLa cells expressing Myc-CK1? 
and probed for REST showing that Myc-CK1? associates with endogenous REST. 
 
Figure 5.	 CK1 directly phosphorylates serine residues in carboxy-terminus of REST.  
(a) Immunoprecipitation of HA from N2A cells expressing WT or mutant HA-REST 
constructs was incubated in the presence or absence of recombinant CK1? and ?
-32P-ATP. Upper, autoradiogram depicting phospho-HA-REST shows that single-point 
mutations S1013A, S1024A and S1030A significantly alter CK1-dependent 
phosphorylation of REST. Lower, summary data. Values for phosphorylated 
HA-REST are normalized to values for HA-REST. (b) Immunoprecipitation of HA from 
N2A cells expressing WT HA-REST, double mutant HA-REST (E1009A/S1013A), and 
triple mutant HA-REST (S1024A/S1027A/S1030A) and was incubated in the 
presence or absence of recombinant CK1? and ?-32P-ATP, Upper, autoradiogram 
depicting phospho-HA-REST shows that the double and triple HA-REST mutants 
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abolish CK1-dependent phosphorylation. Lower, Summary data. (c) 
Immunoprecipitation of HA from N2A cells expressing WT HA-REST, double mutant 
HA-REST (S1013A/S1030A), or quadruple mutant HA-REST 
(S1013A/S1024A/S1027A/ S1030A) with an antibody to HA was incubated in the 
presence or absence of recombinant CK1? and ?-32P-ATP. Upper, autoradiogram 
depicting phospho-HA-REST shows that the double and quadruple HA-REST 
mutants significantly decrease CK1-dependent phosphorylation of REST. Lower, 
summary data. n = 3 per treatment group/ 3 independent experiments. ***, p < 0.001, 
**, p < 0.01, *, p < 0.05. 
 
Figure 6.	 CK1 associates with REST, increases ? -TrCP binding and REST 
ubiquitination.  
(a) Upper, Immunoprecipitation of Flag from HeLa cells expressing myc-CK1?, 
HA-REST and Flag-?-TrCP was subjected to Westerns probed for HA-REST and 
shows that CK1 increases interaction between REST and ? -TrCP. Lower: 
Immunoprecipitation of HA from HeLa cells expressing HA-REST and Myc-CK1? 
was subjected to Westerns and probed for HA-REST, Myc-CK1? and ubiquitin and 
shows that CK1 binds REST and promotes ubiquitination of REST. (b) Upper, 
Representative Western blot showing that two different sequences of 
shRNA-mediated knockdown of ? -TrCP1/2 (? -TrCP1/2 shRNA-1, ? -TrCP1/2 
shRNA-2) in hippocampal neurons increase REST expression.  Lower, summary 
data. n = 3 per treatment group/ 3 independent experiments. ***, p < 0.001, **, p < 
0.01, *, p < 0.05. 
 
Figure 7.	 REST is targeted to the proteasomal degradation pathway in neurons.  
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(a) Upper, representative Western blot showing that the proteasome inhibitor 
lactacystin injected in vivo increases REST abundance and global protein 
ubiquitination in the hippocampal CA1. Lower, summary data. (b) Upper, 
representative Western blot showing that application of the proteasome inhibitor 
lactacystin applied to hippocampal neurons in vitro does not detectably alter ?
-TRCP, but induces upregulation of REST and downregulation of the REST target 
gene GluA2 under control conditions. Oxygen-glucose deprivation (OGD) decreases 
?-TRCP, increases REST and decreases GluA2 in hippocampal neurons in vitro. 
Administration of lactacystin to neurons subjected to OGD does not further alter REST 
or GluA2. Lower, summary data. n = 3 per treatment group in 3 independent 
experiments. ***, p < 0.001.   
 
Figure 8.	 Global ischemia decreases CK1 and upregulates REST in CA1.  
(a) Representative Western blot showing that global ischemia induces a decrease in 
CK1?, CK1?, and ?-TrCP and increase in REST, but does not detectably alter 
Cul1 or HAUSP protein expression in the CA1, assessed at 24 and 48 h after 
ischemia. (b) Summary data. n = 4 - 6 animals per group. ***, p < 0.001, **, p < 0.01, *, 
p < 0.05. 
 
Figure 9.	 The CK1 activator pyrvinium protects CA1 neurons from ischemia-induced 
cell death in vivo.  
(a) Representative images of toluidine blue and Fluoro-Jade staining of CA1 
pyramidal neurons in rats 7 d after global ischemia or sham surgery, followed by icv 
injection of the CK1 activator pyrvinium (1 mM) or vehicle. Scale bars: low 
magnification, 500 ?m; high magnification, 50 ?m. (b) Quantification of dying CA1 
pyramidal neurons as assessed by Fluoro-Jade staining. Pyrvinium rescues 
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ischemia-induced neuronal death in the CA1. n = 5 - 6 animals per group. ***, p < 
0.001. 
 
Figure 10.	 The CK1 activator pyrvinium inhibits REST upregulation and restores 
GluA2 level in CA1 after global ischemia.  
(a) Representative Western blot showing that injection of pyrvinium essentially 
restores the ischemia-induced increase in REST and decrease in the REST target 
GluA2. (b) Summary data. n = 4 - 6 animals per group. **, ## p < 0.01, *,# p < 0.05. 
 
Figure 11. Model depicting a hypothetical mechanism by which CK1 regulates REST 
abundance in differentiated neurons under physiological and pathological conditions.  
Under physiological conditions, CK1 binds and phosphorylates REST at sites within 
two neighboring, but distinct degron motifs. The phosphorylated degrons 
(phospho-degrons) are critical to recognition of REST by the E3 ubiquitin protein 
ligase ?-TrCP, which ubiquitinates and targets REST for proteasomal degradation. 
Global ischemia reduces CK1 and ?-TrCP abundance, which lead to an increase in 
REST in the hippocampal CA1. REST binds to the RE1 element within the promoter 
of target genes such as GluA2 and orchestrates the assembly of mSin3A and 
CoREST, HDACs 1 and 2, G9a and MeCP2. The REST-corepressor complex 
promotes epigenetic remodeling of core histone proteins at the promoter of target 
genes and represses transcription of synaptic proteins. Modified with permission from 
(Frescas and Pagano, 2008; Noh et al., 2012). 
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